ONO-AE-248

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525723

CAS#: 211230-67-0

Description: ONO-AE-248 is a novel selective EP3 receptor agonist.


Chemical Structure

img
ONO-AE-248
CAS# 211230-67-0

Theoretical Analysis

MedKoo Cat#: 525723
Name: ONO-AE-248
CAS#: 211230-67-0
Chemical Formula: C22H36O5
Exact Mass: 380.2563
Molecular Weight: 380.525
Elemental Analysis: C, 69.44; H, 9.54; O, 21.02

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ONO-AE-248

IUPAC/Chemical Name: (Z)-7-[(1R,2R,3R)-3-Methoxy-2-[(E,3S)-3-methoxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid

InChi Key: MXDQOCKVVLKVJS-QKIVIXBWSA-N

InChi Code: InChI=1S/C22H36O5/c1-4-5-8-11-17(26-2)14-15-19-18(20(23)16-21(19)27-3)12-9-6-7-10-13-22(24)25/h6,9,14-15,17-19,21H,4-5,7-8,10-13,16H2,1-3H3,(H,24,25)/b9-6-,15-14+/t17-,18+,19+,21+/m0/s1

SMILES Code: O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](OC)CCCCC)[C@H](OC)CC1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 380.525 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nagano T, Nishiyama R, Sanada A, Mutaguchi Y, Ioku A, Umeki H, Kishimoto S, Yamanaka D, Kimura SH, Takemura M. Prostaglandin E(2) potentiates interferon-γ-induced nitric oxide production in cultured rat microglia. J Neurochem. 2017 Feb;140(4):605-612. doi: 10.1111/jnc.13926. Epub 2017 Feb 2. PubMed PMID: 27973680.

2: Jones VC, Birrell MA, Maher SA, Griffiths M, Grace M, O'Donnell VB, Clark SR, Belvisi MG. Role of EP2 and EP4 receptors in airway microvascular leak induced by prostaglandin E2. Br J Pharmacol. 2016 Mar;173(6):992-1004. doi: 10.1111/bph.13400. PubMed PMID: 26639895; PubMed Central PMCID: PMC4831025.

3: Oba K, Hosono K, Amano H, Okizaki S, Ito Y, Shichiri M, Majima M. Downregulation of the proangiogenic prostaglandin E receptor EP3 and reduced angiogenesis in a mouse model of diabetes mellitus. Biomed Pharmacother. 2014 Oct;68(8):1125-33. doi: 10.1016/j.biopha.2014.10.022. Epub 2014 Oct 31. PubMed PMID: 25465154.

4: Iizuka Y, Kuwahara A, Karaki S. Role of PGE2 in the colonic motility: PGE2 generates and enhances spontaneous contractions of longitudinal smooth muscle in the rat colon. J Physiol Sci. 2014 Mar;64(2):85-96. doi: 10.1007/s12576-013-0295-2. Epub 2013 Oct 30. PubMed PMID: 24170253.

5: Seki K, Hisada T, Kawata T, Kamide Y, Dobashi K, Yamada M, Mori M, Okajima F, Ishizuka T. Oxidative stress potentially enhances FcεRI-mediated leukotriene C4 release dependent on the late-phase increase of intracellular glutathione in mast cells. Biochem Biophys Res Commun. 2013 Sep 27;439(3):357-62. doi: 10.1016/j.bbrc.2013.08.081. Epub 2013 Aug 30. PubMed PMID: 23998930.

6: Shiraishi N, Nomura T, Tanizaki H, Nakajima S, Narumiya S, Miyachi Y, Tokura Y, Kabashima K. Prostaglandin E2-EP3 axis in fine-tuning excessive skin inflammation by restricting dendritic cell functions. PLoS One. 2013 Jul 29;8(7):e69599. doi: 10.1371/journal.pone.0069599. Print 2013. PubMed PMID: 23922752; PubMed Central PMCID: PMC3726673.

7: Aso H, Ito S, Mori A, Suganuma N, Morioka M, Takahara N, Kondo M, Hasegawa Y. Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes. Am J Respir Cell Mol Biol. 2013 Mar;48(3):322-9. doi: 10.1165/rcmb.2012-0158OC. Epub 2012 Dec 6. PubMed PMID: 23221043.

8: Longrois D, Gomez I, Foudi N, Topal G, Dhaouadi M, Kotelevets L, Chastre E, Norel X. Prostaglandin E₂ induced contraction of human intercostal arteries is mediated by the EP₃ receptor. Eur J Pharmacol. 2012 Apr 15;681(1-3):55-9. doi: 10.1016/j.ejphar.2012.01.041. Epub 2012 Feb 12. PubMed PMID: 22342278.

9: Ueta M, Sotozono C, Yokoi N, Kinoshita S. Downregulation of monocyte chemoattractant protein 1 expression by prostaglandin E(2) in human ocular surface epithelium. Arch Ophthalmol. 2012 Feb;130(2):249-51. doi: 10.1001/archopthalmol.2011.1472. PubMed PMID: 22332224.

10: Buckley J, Birrell MA, Maher SA, Nials AT, Clarke DL, Belvisi MG. EP4 receptor as a new target for bronchodilator therapy. Thorax. 2011 Dec;66(12):1029-35. doi: 10.1136/thx.2010.158568. Epub 2011 May 23. PubMed PMID: 21606476; PubMed Central PMCID: PMC3221321.

11: Kobayashi K, Murata T, Hori M, Ozaki H. Prostaglandin E2-prostanoid EP3 signal induces vascular contraction via nPKC and ROCK activation in rat mesenteric artery. Eur J Pharmacol. 2011 Jun 25;660(2-3):375-80. doi: 10.1016/j.ejphar.2011.03.032. Epub 2011 Apr 2. PubMed PMID: 21463619.

12: Mori A, Ito S, Morioka M, Aso H, Kondo M, Sokabe M, Hasegawa Y. Effects of specific prostanoid EP receptor agonists on cell proliferation and intracellular Ca(2+) concentrations in human airway smooth muscle cells. Eur J Pharmacol. 2011 May 20;659(1):72-8. doi: 10.1016/j.ejphar.2011.03.001. Epub 2011 Mar 17. PubMed PMID: 21397595.

13: Foudi N, Kotelevets L, Gomez I, Louedec L, Longrois D, Chastre E, Norel X. Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2) : implication for cardiovascular grafts. Br J Pharmacol. 2011 Jun;163(4):826-34. doi: 10.1111/j.1476-5381.2011.01264.x. PubMed PMID: 21323896; PubMed Central PMCID: PMC3111684.

14: Hosono K, Suzuki T, Tamaki H, Sakagami H, Hayashi I, Narumiya S, Alitalo K, Majima M. Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation. Arterioscler Thromb Vasc Biol. 2011 May;31(5):1049-58. doi: 10.1161/ATVBAHA.110.222356. Epub 2011 Feb 10. PubMed PMID: 21311040.

15: Ueta M. Regulation of ocular surface inflammation by prostaglandin E receptor subtype EP3. Cornea. 2010 Nov;29 Suppl 1:S57-61. PubMed PMID: 20935544.

16: Ueta M, Sotozono C, Nakano M, Taniguchi T, Yagi T, Tokuda Y, Fuwa M, Inatomi T, Yokoi N, Tashiro K, Kinoshita S. Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. J Allergy Clin Immunol. 2010 Dec;126(6):1218-25.e10. doi: 10.1016/j.jaci.2010.08.007. Epub 2010 Oct 13. PubMed PMID: 20947153.

17: Ikeda-Matsuo Y, Tanji H, Ota A, Hirayama Y, Uematsu S, Akira S, Sasaki Y. Microsomal prostaglandin E synthase-1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors. Br J Pharmacol. 2010 Jun;160(4):847-59. doi: 10.1111/j.1476-5381.2010.00711.x. PubMed PMID: 20590584; PubMed Central PMCID: PMC2935993.

18: Rodríguez-Lagunas MJ, Martín-Venegas R, Moreno JJ, Ferrer R. PGE2 promotes Ca2+-mediated epithelial barrier disruption through EP1 and EP4 receptors in Caco-2 cell monolayers. Am J Physiol Cell Physiol. 2010 Aug;299(2):C324-34. doi: 10.1152/ajpcell.00397.2009. Epub 2010 May 19. PubMed PMID: 20484658.

19: Hattori R, Shimizu S, Majima Y, Shimizu T. Prostaglandin E2 receptor EP2, EP3, and EP4 agonists inhibit antigen-induced mucus hypersecretion in the nasal epithelium of sensitized rats. Ann Otol Rhinol Laryngol. 2009 Jul;118(7):536-41. PubMed PMID: 19708495.

20: Honda T, Matsuoka T, Ueta M, Kabashima K, Miyachi Y, Narumiya S. Prostaglandin E(2)-EP(3) signaling suppresses skin inflammation in murine contact hypersensitivity. J Allergy Clin Immunol. 2009 Oct;124(4):809-18.e2. doi: 10.1016/j.jaci.2009.04.029. Epub 2009 Jul 9. PubMed PMID: 19541354.